Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

🚨Update from #ESMO24 Upper GI cancer data 🚨 Dr Lizzy Smyth & Dr Sam Klempner joined us at ESMO to share their insights into new #UpperGI cancer data & the potential impact on clinical practice. 📺 Watch their video update Supported by Bayer #MedEd #oncology #OncTwitter

GI CONNECT powered by COR2ED

2,278 subscribers

160,747 views • 1 year ago •via X (Twitter)

#ESMO24 #UpperGI #MedEd #oncology #OncTwitter

Anya Rossi• Live Now

Private livecam show

1 Comments

Pearse Keane1 year ago

@LizzySmyth1 @KlempnerSam Great to see this pop up in my feed @LizzySmyth1 😀

Related Videos

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED

COR2ED

114,711 views • 9 months ago

Just released! Bladder cancer update from ESMO 25 📺 Prof. Thomas Powles shares his bladder cancer highlights & reviews the latest data from KEYNOTE-905, ALBAN & Imvigor011. This independent programme is supported by COR2ED

Just released! Bladder cancer update from ESMO 25 📺 Prof. Thomas Powles shares his bladder cancer highlights & reviews the latest data from KEYNOTE-905, ALBAN & Imvigor011. This independent programme is supported by COR2ED

COR2ED

229,737 views • 9 months ago

🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. Jenny Seligmann & Dr Dominik Paul Modest share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI

🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. Jenny Seligmann & Dr Dominik Paul Modest share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI

GI CONNECT powered by COR2ED

539,589 views • 2 years ago

🧬Precision oncology in HR+/HER2- metastatic #breastcancer. Dr Callahan and Dr Salgado discuss: Essential #biomarkers (ESR1m, PIK3CA, gBRCA) and their clinical implications, Liquid vs tumour biopsy – when and how? Single gene vs broad panel testing…and much more! 📹 Watch the video highlights in this post 🗣️Get the full conversation/listen to the audio on Spotify/Apple: Supported by an Independent Educational Grant from Thermo Fisher Scientific #MedEd #BCSM #OncTwitter

🧬Precision oncology in HR+/HER2- metastatic #breastcancer. Dr Callahan and Dr Salgado discuss: Essential #biomarkers (ESR1m, PIK3CA, gBRCA) and their clinical implications, Liquid vs tumour biopsy – when and how? Single gene vs broad panel testing…and much more! 📹 Watch the video highlights in this post 🗣️Get the full conversation/listen to the audio on Spotify/Apple: Supported by an Independent Educational Grant from Thermo Fisher Scientific #MedEd #BCSM #OncTwitter

BREAST CANCER CONNECT

112,471 views • 1 year ago

Today, IMA Senior Fellow, Oncology Dr. Angus Dalgleish testified at Senator Ron Johnson's hearing, 'Plausible Mechanisms of COVID-19 Injections Causing Cancer and Attacks on Scientific Publications. Last week, Dr. Dalgleish joined us to discuss his concerns about the exponential rise in cancer cases and issued a call to action for clinicians and researchers working with cancer patients to speak up and share their observations before this trend worsens. Watch now.

Today, IMA Senior Fellow, Oncology Dr. Angus Dalgleish testified at Senator Ron Johnson's hearing, 'Plausible Mechanisms of COVID-19 Injections Causing Cancer and Attacks on Scientific Publications. Last week, Dr. Dalgleish joined us to discuss his concerns about the exponential rise in cancer cases and issued a call to action for clinicians and researchers working with cancer patients to speak up and share their observations before this trend worsens. Watch now.

Independent Medical Alliance

24,462 views • 2 months ago

A stunning clinical observation has set a new course in the fight against cancer. Renowned cancer surgeon Dr. Kathleen Ruddy reveals a medical anomaly that challenges everything we know. After 30 years in oncology, having never witnessed a single case of spontaneous remission, Dr. Ruddy saw three patients experience dramatic responses that could only be attributed to one thing: the repurposed drug Ivermectin. The statistical likelihood of this happening by chance? "It's not zero, but it approaches zero." Faced with this incredible signal, the conventional path—a funded clinical trial—was a dead end. "What do you think the likelihood of that is? That's zero. That's flat-out zero." So, what's the next step? Dr. Ruddy found inspiration in one of medicine's most legendary studies: Framingham. Just as the Framingham Heart Study followed a population over decades without intervention, simply collecting data to make landmark discoveries, Dr. Ruddy is launching a groundbreaking initiative. This will be a Framingham-type observational study for cancer patients. The subjects? Patients who, exercising their right to choose, have already decided to use repurposed, FDA-approved drugs like Ivermectin under their physician's guidance. The central question is powerful in its simplicity: Do drugs like Ivermectin improve survival for cancer patients? This is a pivotal moment for data-driven medicine. It’s a direct response to real-world evidence and a refusal to ignore potential breakthroughs hiding in plain sight. If the signal is confirmed, it could revolutionize oncology. This isn't just observation; it's a mission to follow the data, wherever it leads.

A stunning clinical observation has set a new course in the fight against cancer. Renowned cancer surgeon Dr. Kathleen Ruddy reveals a medical anomaly that challenges everything we know. After 30 years in oncology, having never witnessed a single case of spontaneous remission, Dr. Ruddy saw three patients experience dramatic responses that could only be attributed to one thing: the repurposed drug Ivermectin. The statistical likelihood of this happening by chance? "It's not zero, but it approaches zero." Faced with this incredible signal, the conventional path—a funded clinical trial—was a dead end. "What do you think the likelihood of that is? That's zero. That's flat-out zero." So, what's the next step? Dr. Ruddy found inspiration in one of medicine's most legendary studies: Framingham. Just as the Framingham Heart Study followed a population over decades without intervention, simply collecting data to make landmark discoveries, Dr. Ruddy is launching a groundbreaking initiative. This will be a Framingham-type observational study for cancer patients. The subjects? Patients who, exercising their right to choose, have already decided to use repurposed, FDA-approved drugs like Ivermectin under their physician's guidance. The central question is powerful in its simplicity: Do drugs like Ivermectin improve survival for cancer patients? This is a pivotal moment for data-driven medicine. It’s a direct response to real-world evidence and a refusal to ignore potential breakthroughs hiding in plain sight. If the signal is confirmed, it could revolutionize oncology. This isn't just observation; it's a mission to follow the data, wherever it leads.

Camus

135,440 views • 10 months ago

Dr. Byram Bridle sheds light on the promising potential of ivermectin and fenbendazole in cancer treatment. These affordable, off-patent drugs—originally used as dewormers—have shown early-stage research indicating benefits across a wide range of cancer types. However, the medical community demands randomized controlled trials (RCTs) to validate their efficacy. The challenge? RCTs cost millions, typically funded by pharmaceutical companies. But with no profit to be made from cheap, off-patent drugs like ivermectin and fenbendazole, Big Pharma has little incentive to invest. Dr. Bridle argues this creates a systemic barrier, preventing these potentially game-changing treatments from entering mainstream oncology Dr. Bridle, who has extensively reviewed the literature, calls the early research “fantastic” and urges government intervention. He advocates for taxpayer-funded RCTs to bridge the gap, emphasizing that public investment could unlock these drugs’ potential to transform cancer care. However, Dr. Bridle raises a deeper concern about the cancer industry. At a pharmaceutical-sponsored conference, he was shocked to hear business leaders describe their “ideal” cancer treatment: not a cure, but a lifelong, expensive patented drug that keeps cancer cells at bay while maintaining quality of life. This profit-driven mindset, he notes, clashes with the public’s expectation of curative intent. Dr. Bridle questions whether the cancer industry truly prioritizes finding a cure, given the immense financial stakes. His insights highlight a critical need for reform to prioritize patients over profits

Dr. Byram Bridle sheds light on the promising potential of ivermectin and fenbendazole in cancer treatment. These affordable, off-patent drugs—originally used as dewormers—have shown early-stage research indicating benefits across a wide range of cancer types. However, the medical community demands randomized controlled trials (RCTs) to validate their efficacy. The challenge? RCTs cost millions, typically funded by pharmaceutical companies. But with no profit to be made from cheap, off-patent drugs like ivermectin and fenbendazole, Big Pharma has little incentive to invest. Dr. Bridle argues this creates a systemic barrier, preventing these potentially game-changing treatments from entering mainstream oncology Dr. Bridle, who has extensively reviewed the literature, calls the early research “fantastic” and urges government intervention. He advocates for taxpayer-funded RCTs to bridge the gap, emphasizing that public investment could unlock these drugs’ potential to transform cancer care. However, Dr. Bridle raises a deeper concern about the cancer industry. At a pharmaceutical-sponsored conference, he was shocked to hear business leaders describe their “ideal” cancer treatment: not a cure, but a lifelong, expensive patented drug that keeps cancer cells at bay while maintaining quality of life. This profit-driven mindset, he notes, clashes with the public’s expectation of curative intent. Dr. Bridle questions whether the cancer industry truly prioritizes finding a cure, given the immense financial stakes. His insights highlight a critical need for reform to prioritize patients over profits

Joe Tippens

34,201 views • 1 year ago

🚨 SHOCKING FDA EXPOSÉ: Under Biden, American cancer patients' CELLS were shipped to CHINA for gene-editing—then injected BACK into US bodies WITHOUT proper consent! Dr. Marty Makary just blew the lid off this national security NIGHTMARE. Key FACTS that’ll make your blood boil (2024-2025 data): • 2M+ Americans diagnosed with cancer in 2024—over 5,500 new cases DAILY—yet their DNA was sent to a hostile nation! (Source: American Cancer Society / CDC) • China conducted 11+ human CRISPR trials by 2018, gene-editing cells from 86+ Americans—while the U.S. handed over our genetic data! (Source: Nature, MIT Technology Review) • Biden’s Dec 2024 FDA exemption allowed this—Trump-Vance FDA halted all new trials in June 2025 to protect American DNA! (Source: official announcement) How deep does this betrayal go?

🚨 SHOCKING FDA EXPOSÉ: Under Biden, American cancer patients' CELLS were shipped to CHINA for gene-editing—then injected BACK into US bodies WITHOUT proper consent! Dr. Marty Makary just blew the lid off this national security NIGHTMARE. Key FACTS that’ll make your blood boil (2024-2025 data): • 2M+ Americans diagnosed with cancer in 2024—over 5,500 new cases DAILY—yet their DNA was sent to a hostile nation! (Source: American Cancer Society / CDC) • China conducted 11+ human CRISPR trials by 2018, gene-editing cells from 86+ Americans—while the U.S. handed over our genetic data! (Source: Nature, MIT Technology Review) • Biden’s Dec 2024 FDA exemption allowed this—Trump-Vance FDA halted all new trials in June 2025 to protect American DNA! (Source: official announcement) How deep does this betrayal go?

Valerie Anne Smith

200,862 views • 8 months ago

🚨 SHOCKING DISCOVERY THEY BURIED: Hydroxychloroquine doesn’t just fight viruses — it turns viruses into precision-guided cancer killers. It allows viruses to attack cancer cells while leaving healthy cells completely untouched. This comes straight from Dr. Richard Urso (ophthalmologist and member of America’s Frontline Doctors) in a powerful presentation. Why was this information suppressed and the data obscured? Because a cheap, decades-old drug that could selectively destroy cancer would be catastrophic for the multi-trillion-dollar cancer industry. They don’t want you to know this. They want you dependent on expensive treatments forever. The truth is out. Share it before it gets buried again.

🚨 SHOCKING DISCOVERY THEY BURIED: Hydroxychloroquine doesn’t just fight viruses — it turns viruses into precision-guided cancer killers. It allows viruses to attack cancer cells while leaving healthy cells completely untouched. This comes straight from Dr. Richard Urso (ophthalmologist and member of America’s Frontline Doctors) in a powerful presentation. Why was this information suppressed and the data obscured? Because a cheap, decades-old drug that could selectively destroy cancer would be catastrophic for the multi-trillion-dollar cancer industry. They don’t want you to know this. They want you dependent on expensive treatments forever. The truth is out. Share it before it gets buried again.

Dr. Dawn Michael

741,917 views • 1 month ago

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter

David Fajgenbaum, MD

55,740 views • 1 year ago

Training robot foundation models faces two key hurdles: how to get enough data to train an effective model, and how to make sure that new skills can be acquired quickly. The team at Rhoda AI believes that the answer is training Direct Video Action models from web data. Web data is plentiful, to the point where Rhoda can train their base model on hundreds of years of video data. And then, with the addition of robot data, they can quickly adapt it to new tasks with as little as 20 hours of in-domain data, performing complex, multi-step manipulation tasks with their purpose-built video foundation model. Tongzhou Mu 🤖🦾🦿 Eric Chan and Changan Chen joined us to talk more about their approach. Watch Episode #79 of RoboPapers, with Michael Cho - Rbt/Acc, Chris Paxton, and Jiafei Duan, to learn more!

Training robot foundation models faces two key hurdles: how to get enough data to train an effective model, and how to make sure that new skills can be acquired quickly. The team at Rhoda AI believes that the answer is training Direct Video Action models from web data. Web data is plentiful, to the point where Rhoda can train their base model on hundreds of years of video data. And then, with the addition of robot data, they can quickly adapt it to new tasks with as little as 20 hours of in-domain data, performing complex, multi-step manipulation tasks with their purpose-built video foundation model. Tongzhou Mu 🤖🦾🦿 Eric Chan and Changan Chen joined us to talk more about their approach. Watch Episode #79 of RoboPapers, with Michael Cho - Rbt/Acc, Chris Paxton, and Jiafei Duan, to learn more!

RoboPapers

24,475 views • 3 months ago

🚨 Dr. James Lyons-Weiler just sounded the alarm: A new Michigan bill would FORCE schools to post kids’ vaccination data publicly. “Imagine having a bill that will compel schools, K-12, to disseminate immunization data to [the] Michigan Department of HHS.” “That families could be notified by email that their child’s vaccination status is different from those of their peers.” “This is a form of coercion that puts the family at risk of stigma and harassment.” “Schools having to post the data on websites and display physical notices? Come on.” “This … can lead to conflict between the child … and the parents who may have very good reasons.” James Lyons-Weiler

🚨 Dr. James Lyons-Weiler just sounded the alarm: A new Michigan bill would FORCE schools to post kids’ vaccination data publicly. “Imagine having a bill that will compel schools, K-12, to disseminate immunization data to [the] Michigan Department of HHS.” “That families could be notified by email that their child’s vaccination status is different from those of their peers.” “This is a form of coercion that puts the family at risk of stigma and harassment.” “Schools having to post the data on websites and display physical notices? Come on.” “This … can lead to conflict between the child … and the parents who may have very good reasons.” James Lyons-Weiler

Children’s Health Defense

17,124 views • 6 months ago

Introducing the Future of AI-Powered Sports Data with $FXI.⚡️ We’re not just talking about innovation, we’re building it. 🚀 From #AI-driven data capture to on-chain validation and data monetization, the FX1 ecosystem is rewriting the rules of the sports and data economy. Our platform empowers leagues, teams, and creators to unlock the full potential of their data with cutting-edge AI solutions. 🧠 Why FX1? ➡️ AI-Powered Precision: Transform raw sports data into actionable insights. ➡️ Data Validation on Chain: Building trust in the data economy through blockchain. ➡️ AI-Powered Revenue Streams: Use sports data to drive predictive analytics, odds modeling, and other high-value solutions that unlock new ways to monetize. FX1 is leading the charge in AI innovation, creating a seamless bridge between sports, blockchain, and the data economy. This isn’t just evolution - it’s a revolution. 💡 The future of sports is here. And it’s powered by AI. 🤖 Watch the full video and see how we’re turning vision into reality. 👇

Introducing the Future of AI-Powered Sports Data with $FXI.⚡️ We’re not just talking about innovation, we’re building it. 🚀 From #AI-driven data capture to on-chain validation and data monetization, the FX1 ecosystem is rewriting the rules of the sports and data economy. Our platform empowers leagues, teams, and creators to unlock the full potential of their data with cutting-edge AI solutions. 🧠 Why FX1? ➡️ AI-Powered Precision: Transform raw sports data into actionable insights. ➡️ Data Validation on Chain: Building trust in the data economy through blockchain. ➡️ AI-Powered Revenue Streams: Use sports data to drive predictive analytics, odds modeling, and other high-value solutions that unlock new ways to monetize. FX1 is leading the charge in AI innovation, creating a seamless bridge between sports, blockchain, and the data economy. This isn’t just evolution - it’s a revolution. 💡 The future of sports is here. And it’s powered by AI. 🤖 Watch the full video and see how we’re turning vision into reality. 👇

FX1

23,913 views • 1 year ago

“Leave the cocooning to the caterpillars.” Dr. Robert Malone is sounding the alarm on people pushing policies that require vaccination to see newborn babies, saying the practice is not supported by science. “There’s a policy that is being advocated by many using the hashtag ‘no vax, no visit.’” “What I’m talking about is called cocooning.” “Parents increasingly are saying that grandparents… can’t be around their new grandchild if they haven’t been fully vaccinated.” “This was a policy promoted by the ACIP historically without any data.” (Video from Weekly MAHA Media Hub)

“Leave the cocooning to the caterpillars.” Dr. Robert Malone is sounding the alarm on people pushing policies that require vaccination to see newborn babies, saying the practice is not supported by science. “There’s a policy that is being advocated by many using the hashtag ‘no vax, no visit.’” “What I’m talking about is called cocooning.” “Parents increasingly are saying that grandparents… can’t be around their new grandchild if they haven’t been fully vaccinated.” “This was a policy promoted by the ACIP historically without any data.” (Video from Weekly MAHA Media Hub)

MAHA Action

86,703 views • 7 months ago

Ivermectin & Fenbendazole Cancer Secrets Revealed w/ Dr. William Makis Remarkable success stories are pouring in from people using Ivermectin and Fenbendazole to combat cancer. Mel Gibson dropped a bombshell on Joe Rogan’s podcast, revealing that three of his friends had “stage four cancer,” and now “all three of them don’t have cancer right now at all.” “And they had some serious stuff going on,” Gibson emphasized. Dr. William Makis, who treated one of Gibson’s friends, has been rigorously researching the anti-cancer potential of Ivermectin and Fenbendazole over the past two years. During that time, he discovered, “There are over 100 papers on the success of Ivermectin and cancer.” “Ivermectin can actually kill cancer stem cells,” Dr. Makis explained, noting that it targets the cells “that chemo can’t kill.” He added, “It can also reverse resistance that cancer cells develop to certain types of chemotherapy.” The benefits extend further. “It [Ivermectin] makes cancer cells susceptible to radiation treatment as well. And so it’s a radiosensitizer,” he shared. Yet, research into these applications has been neglected. “Big Pharma has completely abandoned it. Ivermectin is off-patent. No one’s going to make money on it,” Dr. Makis pointed out. Taking action where others haven’t, Dr. Makis applied his findings to his practice. “I have over 1,000 cancer patients who are on either a combination of Ivermectin and Fenbendazole or Ivermectin and Mebendazole,” he shared. Some of his patients were “given a terminal diagnosis” but are now “cancer-free” or have their “cancer under control.” “Patients, for example, who are taking combinations of chemo and Ivermectin or radiation and Ivermectin are seeing dramatic results that oncologists have never seen, that radiation oncologists have never seen,” Dr. Makis shared. “Tumors shrinking down to almost nothing, liver metastases disappearing, brain metastases disappearing.” “There are hundreds, if not thousands, of testimonials” documenting the success stories of Ivermectin and Fenbendazole, Dr. Makis added, offering hope to patients seeking alternatives. He strongly believes that “the future of cancer care is in repurposed drugs.” For more information on the use of Ivermectin and Fenbendazole for cancer, follow Dr. William Makis (MakisMD) on 𝕏. --> MakisMD (See 9 More Revealing Stories Below)

Ivermectin & Fenbendazole Cancer Secrets Revealed w/ Dr. William Makis Remarkable success stories are pouring in from people using Ivermectin and Fenbendazole to combat cancer. Mel Gibson dropped a bombshell on Joe Rogan’s podcast, revealing that three of his friends had “stage four cancer,” and now “all three of them don’t have cancer right now at all.” “And they had some serious stuff going on,” Gibson emphasized. Dr. William Makis, who treated one of Gibson’s friends, has been rigorously researching the anti-cancer potential of Ivermectin and Fenbendazole over the past two years. During that time, he discovered, “There are over 100 papers on the success of Ivermectin and cancer.” “Ivermectin can actually kill cancer stem cells,” Dr. Makis explained, noting that it targets the cells “that chemo can’t kill.” He added, “It can also reverse resistance that cancer cells develop to certain types of chemotherapy.” The benefits extend further. “It [Ivermectin] makes cancer cells susceptible to radiation treatment as well. And so it’s a radiosensitizer,” he shared. Yet, research into these applications has been neglected. “Big Pharma has completely abandoned it. Ivermectin is off-patent. No one’s going to make money on it,” Dr. Makis pointed out. Taking action where others haven’t, Dr. Makis applied his findings to his practice. “I have over 1,000 cancer patients who are on either a combination of Ivermectin and Fenbendazole or Ivermectin and Mebendazole,” he shared. Some of his patients were “given a terminal diagnosis” but are now “cancer-free” or have their “cancer under control.” “Patients, for example, who are taking combinations of chemo and Ivermectin or radiation and Ivermectin are seeing dramatic results that oncologists have never seen, that radiation oncologists have never seen,” Dr. Makis shared. “Tumors shrinking down to almost nothing, liver metastases disappearing, brain metastases disappearing.” “There are hundreds, if not thousands, of testimonials” documenting the success stories of Ivermectin and Fenbendazole, Dr. Makis added, offering hope to patients seeking alternatives. He strongly believes that “the future of cancer care is in repurposed drugs.” For more information on the use of Ivermectin and Fenbendazole for cancer, follow Dr. William Makis (MakisMD) on 𝕏. --> MakisMD (See 9 More Revealing Stories Below)

The Vigilant Fox 🦊

1,292,701 views • 1 year ago

🚨 IVERMECTIN AND CANCER: WHAT THE RESEARCH ACTUALLY SHOWS A researcher recently shared what they found after looking into Ivermectin and cancer. They discovered over 300 peer-reviewed papers on PubMed examining Ivermectin in cancer. While most of this research is preclinical (cell lines, mice, and rats), the body of work is extensive and covers many different mechanisms. Key points from the research include: ✅ Ivermectin appears to target cancer stem cells, which standard chemotherapy often does not effectively kill. ✅ It can help reverse multi-drug resistance in cancer cells and may sensitise them to chemotherapy. ✅ It acts as a radio sensitizer, potentially making cancer cells more responsive to radiation. ✅ It can inhibit angiogenesis, limiting the tumor’s ability to form new blood vessels. ✅ It may inhibit enzymes involved in cancer cell detachment and spread, reducing the potential for metastasis. The researcher noted that Ivermectin is an off-patent, low-cost drug. Because of this, there has been little financial incentive to fund large-scale human trials in oncology, which is why most of the data remains preclinical.

🚨 IVERMECTIN AND CANCER: WHAT THE RESEARCH ACTUALLY SHOWS A researcher recently shared what they found after looking into Ivermectin and cancer. They discovered over 300 peer-reviewed papers on PubMed examining Ivermectin in cancer. While most of this research is preclinical (cell lines, mice, and rats), the body of work is extensive and covers many different mechanisms. Key points from the research include: ✅ Ivermectin appears to target cancer stem cells, which standard chemotherapy often does not effectively kill. ✅ It can help reverse multi-drug resistance in cancer cells and may sensitise them to chemotherapy. ✅ It acts as a radio sensitizer, potentially making cancer cells more responsive to radiation. ✅ It can inhibit angiogenesis, limiting the tumor’s ability to form new blood vessels. ✅ It may inhibit enzymes involved in cancer cell detachment and spread, reducing the potential for metastasis. The researcher noted that Ivermectin is an off-patent, low-cost drug. Because of this, there has been little financial incentive to fund large-scale human trials in oncology, which is why most of the data remains preclinical.

Dr. Zakaria MD

20,137 views • 24 days ago